| CAS ID: | 211915-06-9 |
| Molecular Formula: | C34H41N7O5 |
| Molecular Weight: | 627.8 g/mol |
| Monoisotopic Mass: | 627.3169 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | PRADAXA | DABIGATRAN ETEXILATE MESYLATE | BIBR-1048 | DABIGATRAN ETEXILATE | BIBR 1048 MS | BIBR 1048 BS RS1 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44) | See All |
| InChI Key: | KSGXQBZTULBEEQ-UHFFFAOYSA-N | |
| Smiles: | CCCCCCOC(=O)\N=C(/N)\c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c4ccccn4)cc1 | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT01546883 | Disease | Cardiac fibrosis |
| Phase | Phase 4 | Status | Terminated |
| First Received | March 7, 2012 | Last Verified | October 12, 2015 |
| Sponsor | University of Utah | ||
| PubChem: | 6445226 |
| ChEMBL: | CHEMBL539697 |